Syndax Pharmaceuticals To Present At The SITC 31st Annual Scientific Meeting

WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster presentations at the upcoming Society for Immunotherapy in Cancer (SITC) 31 st Annual Scientific Meeting being held November 9-13, 2016 in National Harbor, Maryland.

The following Syndax-sponsored posters to be presented include:

Title: Dose escalation/confirmation results of ENCORE 601, a phase 1b/2 open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) Poster Number: 221 Date and Time: Friday, November 11 from 12:15-1:30 PM ET Track: Combinations: Immunotherapy/Immunotherapy Presenter: Melissa L. Johnson, MD

Title: Targeting colony stimulating factor-1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted antibody Poster Number:  421 Date and Time: Friday, November 11 from 12:15-1:30 PM ET Track: Tumor Microenvironment Presenter: Peter Ordentlich, Ph.D

Additional poster presentations highlighting entinostat include:

Title: Effect of the class I-HDAC inhibitor entinostat and the pan-HDAC inhibitor vorinostat on peripheral immune cell subsets Poster Number: 207 Date and Time: Friday, November 11 from 12:15-1:30 PM ET Track: Combinations: Immunotherapy/Immunotherapy Presenter: Lauren Lepone, Ph.D

Title: Modulation of antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by the anti-PD-L1 antibody avelumab on human lung and prostate carcinoma cell lines using the HDAC inhibitors vorinostat and entinostat Poster Number: 212 Date and Time: Saturday, November 12 from 11:45 AM-1:00 PM ET Track: Combinations: Immunotherapy/Immunotherapy Presenter: Sofia R. Gameiro, Ph.D

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Why You Should Never, Ever Trade on Headlines